At a glance
An ultrashort peptide discussed in cell regulation and tissue models.
This profile separates the compound’s scientific background from specification-specific preparation and source schedules. Begin with the research findings and limitations, then select the formulation you want to examine.
How it works
Potential benefits & side effects
Interpret each outcome in the context of the study population, formulation and evidence type. Research findings do not establish a personal treatment outcome.
Potential benefits & research findings
The source describes laboratory findings across several systems. These observations do not establish a general liver, digestive or anti-aging benefit.[1][2][6]
Read the original publications to see the measured endpoints, comparator, duration and uncertainty. Mechanistic plausibility and a favorable experimental result are different from demonstrated clinical benefit.
Side effects & evidence limitations
Interpret the reported adverse effects together with the study population, route and observation period. Small or short studies can miss uncommon and delayed harms. Evidence from a related compound does not establish the safety of Ovagen.
Source-reported adverse effects and cautions
Sources are available for independent reading. Individual claims and research schedules have not yet undergone an independent clinical review by Pep Science.
- Editorial responsibility
- Pep Science editorial desk
- Last independent review
- Not yet recorded
SPECIFICATIONS & SOURCE SCHEDULES
Explore a vial size
Select the exact formulation. Vial content, target dose and prepared concentration are different measurements.
Showing 20 mg · 1 source tables
Standard / Gradual Approach (2 mL = 10 mg/mL)
| Week | Daily Dose (μg) | Units (per injection) (mL) |
|---|---|---|
| Weeks 1–2 | 10 μg (0.01 mg) | 0.1 units (0.001 mL) |
| Weeks 3–4 | 20 μg (0.02 mg) | 0.2 units (0.002 mL) |
| Weeks 5–6 | 50 μg (0.05 mg) | 0.5 units (0.005 mL) |
| Weeks 7–8 | 100 μg (0.1 mg) | 1 unit (0.01 mL) |
| Weeks 9–16 | 100–150 μg (0.1–0.15 mg) | 1–1.5 units (0.01–0.015 mL) |
Frequency: Inject once daily subcutaneously. Because all per-administration volumes are ≤1.5 units (≤0.015 mL), use 30-unit or 50-unit insulin syringes for improved readability and accuracy. Titrate slowly by adding 10–20 μg (0.1–0.2 units) every 1–2 weeks as tolerated[3].
Additional schedule context & duration
Concise summary of the once-daily regimen.
- Goal: Support gastrointestinal and hepatic tissue bioregulation over time[1].
- Schedule: Daily subcutaneous injections for 16 weeks with gradual titration.
- Dose Range: 10–150 μg daily with slow escalation.
- Reconstitution: 2.0 mL per 20 mg vial (10 mg/mL) for precise microgram measurements.
- Storage: Lyophilized frozen; reconstituted refrigerated; avoid repeated freeze–thaw.
Suggested daily titration approach.
- Start: 10 μg daily for Weeks 1–2; increase to 20 μg for Weeks 3–4.
- Escalate: 50 μg for Weeks 5–6; then 100 μg for Weeks 7–8.
- Maintenance: 100–150 μg daily for Weeks 9–16.
- Frequency: Once per day (subcutaneous).
- Timing: Any consistent time; rotate injection sites.
Preparation
Reconstitution Steps
- Draw 2.0 mL bacteriostatic water with a sterile syringe.
- Inject slowly down the vial wall; avoid foaming.
- Gently swirl/roll until dissolved (do not shake).
- Label and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.
Storage Instructions
Proper storage preserves peptide quality[4][5].
- Lyophilized: Store at −20 °C (−4 °F) or colder in dry, dark conditions; for long-term stability, −80 °C (−112 °F) is optimal.
- Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); use within a few days or aliquot and freeze to minimize hydrolysis.
- Do not store thawed solution longer than 1–2 days at 2–8 °C; avoid freeze–thaw cycles.
- Allow vials to reach room temperature before opening to reduce condensation uptake.
Injection Technique
General subcutaneous guidance from clinical best-practice resources[8].
- Clean the vial stopper and skin with 60–70% alcohol; allow to dry[8].
- Pinch a skinfold; insert the needle at 45–90° into subcutaneous tissue[9][10].
- Do not aspirate for subcutaneous injections; inject slowly and steadily[8].
- Rotate sites systematically (abdomen, thighs, upper arms) to avoid tissue irritation; keep at least ~2 cm between injections on the same area.
- Use a 23–25 gauge needle (5/8″ length) or standard insulin syringe needles (28–31G)[10].
Materials & quantity planning
Source materials checklist · 20 mg
Plan based on a 16-week daily protocol with gradual titration. One 20 mg vial provides approximately 13,510 μg total usage over 16 weeks, so a single vial is sufficient for the full course.
-
Peptide Vials (Ovagen, 20 mg each):
- 16 weeks: 1 vial (with excess remaining)
-
Insulin Syringes (U-100, 30-unit or 50-unit recommended):
- Per week: 7 syringes (1/day)
- 16 weeks: 112 syringes (recommend ~120 with extras)
-
Bacteriostatic Water (10 mL bottles): Use 2.0 mL per vial for reconstitution.
- 16 weeks (1 vial): 2 mL → 1 × 10 mL bottle
-
Alcohol Swabs: One for the vial stopper + one for the injection site each day.
- Per week: 14 swabs (2/day)
- 16 weeks: 224 swabs → recommend 3 × 100-count boxes
Calculate a phased quantity
Enter each finite phase from the schedule you are studying. Open-ended phases need an explicit duration. Calculation uses 20 mg per vial and 2 mL per vial.
Complete each phase to calculate totals.
Quantity estimates exclude preparation losses and expiry. Follow the formulation’s handling and disposal requirements.
FOLLOW THE EVIDENCE
References & further reading
Original publications and source documents cited across this product’s variants. A listed source is not an independent endorsement of a dosing schedule.
- 02
Research publication
PubMed — Advances in Gerontology — Tripeptides slow down aging process in renal cell culture (Khavinson et al., 2014) (opens in a new tab)pubmed.ncbi.nlm.nih.gov
Back to overview ↑ - 04
Source document
Sigma-Aldrich — Peptide Handling and Storage Guide (aliquoting, freeze–thaw, labeling) (opens in a new tab)www.sigmaaldrich.com
Back to overview ↑ - 05
- 06
Research publication
PubMed — Biochemistry — HIV-1 protease inhibitors: enthalpic versus entropic optimization of binding affinity (opens in a new tab)pubmed.ncbi.nlm.nih.gov
Back to overview ↑ - 07
- 08
Public health resource
NCBI Bookshelf — WHO — Best practices for injections and related procedures (asepsis, preparation, administration) (opens in a new tab)www.ncbi.nlm.nih.gov
Back to overview ↑ - 09
Public health resource
CDC — Vaccine administration: subcutaneous route (angle/site guidance) (opens in a new tab)www.cdc.gov
Back to overview ↑ - 10
Public health resource
CDC (Subcut Injection PDF) — Technique diagram and site guidance for subcutaneous injections (opens in a new tab)www.cdc.gov
Back to overview ↑
Continue exploring
Related topics are not interchangeable compounds or formulations.